Welcome to our dedicated page for Aptose Bioscienc SEC filings (Ticker: APTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aptose Biosciences Inc. filings document regulatory events for a Canadian clinical-stage oncology issuer developing tuspetinib-based therapy for acute myeloid leukemia. Recent 8-K disclosures cover results of operations, Regulation FD communications, shareholder voting, changes in the independent registered public accounting firm, and executive retention award agreements.
The filing record also includes a Form 25 notification relating to removal of the company’s common shares from Nasdaq listing and registration under Section 12(b) of the Exchange Act. Aptose’s disclosures therefore center on clinical-stage operating results, governance approvals, auditor oversight, capital and listing status, and material-event reporting.
Aptose Biosciences (NASDAQ:APTO) filed an 8-K disclosing a new US$8.5 million secured term loan agreement with Hanmi Pharmaceutical dated 20 Jun 2025.
Key terms:
- Facility available in up to 5 advances (≤US$2.5 m each) through 31 Dec 2025; non-revolving.
- Interest: 6% fixed; balloon repayment of all principal and accrued interest on 31 Aug 2028.
- Secured by first-ranking liens on all present and after-acquired property of Aptose and guaranteed by subsidiaries.
- Purpose limited to continued clinical development and operating costs related to Tuspetinib, an AML therapy.
- Contains customary covenants and default provisions; any re-borrowings prohibited.
The filing also triggers Item 2.03 for creation of a direct financial obligation. The debt adds leverage but supplies non-dilutive capital for ongoing trials.
Aptose Biosciences Inc. (NASDAQ: APTO) filed a Form 8-K dated June 20, 2025 to disclose an Item 7.01 Regulation FD communication. The filing states that the company issued a press release on the same date, attached as Exhibit 99.1.
The 8-K expressly notes that, under General Instruction B.2, the press release is being “furnished” rather than “filed”, meaning it is not incorporated into Exchange Act reports unless specifically referenced. No financial results, strategic transactions, or operational updates are contained in the 8-K itself, and the exhibit text is not included in the filing excerpt provided.
Aptose Biosciences Inc. (APTO) filed a Form 8-K dated June 18, 2025 to disclose the immediate resignation of director Carol Ashe, effective June 16, 2025.
The company states that Ms. Ashe’s departure was not related to any disagreement regarding operations, policies, or practices. Chairman, President & CEO William G. Rice, Ph.D. signed the filing on behalf of the board. No other management changes, financial data, or strategic transactions were reported.